Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Sandoz

    - PMLiVE

    Sandoz launches first and only multiple sclerosis biosimilar in US

    The treatment is FDA-approved to treat MS and Crohn’s disease

    - PMLiVE

    Sandoz to acquire Just-Evotec Biologics to strengthen biosimilar development and manufacturing capabilities

    Acquisition will add in-house continuous manufacturing expertise and expand Sandoz’s biosimilar production capacity

    - PMLiVE

    Sandoz receives FDA approval for first denosumab biosimilars Wyost and Jubbonti

    The biosimilars have been authorised for all indications covered by Amgen's reference medicines

    - PMLiVE

    Sandoz separates from Novartis as an independent spin-off company

    The split allows Sandoz to strengthen its position in generics and biosimilars

    - PMLiVE

    Sandoz biosimilar receives EC approval to treat MS

    Tyruko is the first and only biosimilar treatment for relapsing-remitting MS in Europe

    - PMLiVE

    Sandoz’s Tyruko approved by FDA as first biosimilar for relapsing multiple sclerosis

    The disease-modifying therapy is approved to treat all indications covered by Tysabri

    - PMLiVE

    Sandoz granted positive CHMP opinion for multiple sclerosis biosimilar

    The neurological disease affects approximately 2.8 million people worldwide

    - PMLiVE

    Sandoz launches high-concentration biosimilar of AbbVie’s Humira in the US

    Hyrimoz HCF is approved to treat indications including rheumatoid arthritis and Crohn’s disease

    - PMLiVE

    Sandoz and Just-Evotec Biologics announce multi-year biosimilar partnership

    The Novartis unit will aim to expand its current pipeline of biosimilars to about 24 candidates

    - PMLiVE

    Sandoz’s biosimilar denosumab application accepted by FDA for osteoporosis

    More than ten million adults in the US alone over the age of 50 are estimated to have the condition

    - PMLiVE

    Sandoz’s high concentration Hyrimoz formulation recommended for use in EU

    The recommendation includes multiple indications such as rheumatoid arthritis and Crohn’s disease

    - PMLiVE

    Sandoz to invest €50m in Austrian manufacturing facility to meet global antibiotic demand

    Amoxicillin and other vital penicillin products will benefit from the investment

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links